PK and Safety of ALKS 5461 in Renal Impairment

Phase 1, open-label, single-arm trial of buprenorphine + samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Primary endpoints: Area under the plasma concentration versus time curve from time 0 to infinity, Area under the plasma concentration versus time curve from time 0 to time of last measurable concentration and 1 more. Started Jul 2015; status: completed.